Fig. 3From: Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approachReturn on investment of precision and non-precision oncology medicines, restricted from 1997 to 2015. A Precision oncology medicines. B Non-precision oncology medicinesBack to article page